Davunetide (acetate) (Synonyms: AL-108, NAP, NAPVSIPQ) |
| رقم الكتالوجGC49913 |
A neuroprotective ADNP-derived peptide
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Davunetide is a neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP).1 It promotes tubulin assembly in a cell-free assay when used at a concentration of 1 fM.2 Davunetide (1 fM) protects against cytotoxicity induced by tetrodotoxin , a peptide derived from amyloid-β (Aβ), or zinc in isolated neonatal cerebral cortical cells.1,2 Intravitreal administration of davunetide (4 µl of a 100 µg/ml solution) inhibits increases in cleaved caspase-3 and decreases in Bcl-2 levels in retina isolated from streptozotocin-induced diabetic rats.3 It improves survival in a superoxide dismutase 1 mutant (SOD1G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS) when administered at 10 µg/animal.4 Davunetide prevents decreases in brain choline acetyltransferase (ChAT) activity and prevents memory deficits in the Morris water maze in an Apoe-/- mouse model of neurodegeneration.1
1.Bassan, M., Zamostiano, R., Davidson, A., et al.Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptideJ. Neurochem.72(3)1283-1293(1999) 2.Divinski, I., Mittelman, L., and Gozes, I.A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxicationJ. Biol. Chem.279(27)28531-28538(2004) 3.Scuderi, S., D’Amico, A.G., Castorina, A., et al.Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic deathJ. Mol. Neurosci.54(3)395-404(2014) 4.Jouroukhin, Y., Ostritsky, R., Assaf, Y., et al.NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transportNeurobiol. Dis.5679-94(2013)
| Cas No. | SDF | ||
| المرادفات | AL-108, NAP, NAPVSIPQ | ||
| Canonical SMILES | O=C([C@H]1N(CCC1)C([C@H](C)NC([C@@H](N)CC(N)=O)=O)=O)N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N2[C@@H](CCC2)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)=O)=O.CC(O)=O | ||
| Formula | C36H60N10O12 • XC2H4O2 | M.Wt | 824.9 |
| الذوبان | DMF: 1 mg/ml,DMSO: 1 mg/ml,Ethanol: insol,PBS (pH 7.2): 10 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2123 mL | 6.0613 mL | 12.1227 mL |
| 5 mM | 0.2425 mL | 1.2123 mL | 2.4245 mL |
| 10 mM | 0.1212 mL | 0.6061 mL | 1.2123 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *